Deidre Wilkins

AstraZeneca (Finland) — Finland

Medicine · Health Sciences

22h-index1.4kcitations49works5.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Respiratory viral infections research(21), SARS-CoV-2 and COVID-19 Research(6), Neonatal Respiratory Health Research(6), Coagulation, Bradykinin, Polyphosphates, and Angioedema(6), Neuroscience and Neuropharmacology Research(5)

Publications49 total

Reliability of RSV Antigen Diagnostic Tests in the Presence of Nirsevimab
The Pediatric Infectious Disease Journal·2026Open Access
P-1521. Prophylactic Immunization with Nirsevimab Does Not Impair the Development of Natural Antibody Responses to the Pre-fusion Conformation of the Respiratory Syncytial Virus Fusion Protein
Open Forum Infectious Diseases·2026Open Access
185. Nirsevimab Binding Site Conservation in RSV F Protein between 2019 and 2024: Analysis of Sequencing Data from the US OUTSMART-RSV Surveillance Study and Public Databases
Open Forum Infectious Diseases·2026Open Access
P-2179. Nirsevimab in Patient Samples Does Not Interfere with Respiratory Syncytial Virus (RSV) Detection by Commercially Available Rapid Antigen Tests
Open Forum Infectious Diseases·2025Open Access
Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY)
Clinical Infectious Diseases·2024· 11 citedOpen Access
Harmonization of Vaccine Ligand Binding Assays Validation
Bioanalysis·2024· 3 citedOpen Access
RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing
PEDIATRICS·2024· 26 citedOpen Access
Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY)
Vaccine·2024· 3 citedOpen Access
Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity
Frontiers in Immunology·2024· 2 citedOpen Access
Author Correction: Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants
Nature Medicine·2024· 2 citedOpen Access
The genomic evolutionary dynamics and global circulation patterns of respiratory syncytial virus
Nature Communications·2024· 21 citedOpen Access
Author Correction: Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
Nature Communications·2024· 2 citedOpen Access
2641. Nirsevimab binding-site conservation in RSV F protein between 2015 and 2022: The US OUTSMART-RSV surveillance study
Open Forum Infectious Diseases·2023· 3 citedOpen Access
1934. Nirsevimab is Associated with Higher and More Sustained RSV Neutralizing Antibody Responses Compared with Standard of Care Palivizumab: Observations from a 2:1 Randomized, Phase 2/3 Trial in Medically Vulnerable Children (MEDLEY)
Open Forum Infectious Diseases·2023· 2 citedOpen Access
Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection
Frontiers in Immunology·2023· 28 citedOpen Access
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
Nature Communications·2023· 63 citedOpen Access
Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants
Nature Medicine·2023· 112 citedOpen Access
Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data
The Lancet Infectious Diseases·2023· 97 cited
Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated
Frontiers in Immunology·2023· 12 citedOpen Access
AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infection
Cell Reports Medicine·2022· 22 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Elizabeth J. Kelly(18), Anastasia A. Aksyuk(15), Tonya Villafana(13), Kevin M. Tuffy(12), Mark T. Esser(11), Bahar Ahani(9), Michael E. Abram(8), Amanda Leach(8), David E. Tabor(7), Ulrika Wählby Hamrén(7), Ann Marie Stanley(7), Clay W. Scott(6), Hong Ji(6), Stephen G. Farmer(5), Joseph B. Domachowske(5), Robert Jan Lebbink(4), Leyla Kragten‐Tabatabaie(4), Yue Chang(4), Tyler Brady(4), Marta C. Nunes(4)